Dow Jones

39 872,99

0,17%

DAX

Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

S'inscrire

VTRS

Viatris (VTRS)

Viatris Inc

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:NASDAQ:VTRS

1 2 3 4 5 6 Suivant >>

Date	Heure	Source	Titre	Symbole	Société
21/05/2024	12h59	PR Newswire (US)	Viatris Publishes 2023 Sustainability Report: Building Sustainable Access at Scale	NASDAQ:VTRS	Viatris Inc
09/05/2024	13h47	IH Market News	U.S. Index Futures Dip, Bank of England Holds Interest Rates at 5.25%	NASDAQ:VTRS	Viatris Inc
09/05/2024	13h44	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VTRS	Viatris Inc
09/05/2024	12h59	PR Newswire (US)	Viatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance Ranges	NASDAQ:VTRS	Viatris Inc
02/05/2024	23h00	PR Newswire (US)	Viatris to Participate in the BofA Securities 2024 Health Care Conference	NASDAQ:VTRS	Viatris Inc
01/05/2024	12h59	PR Newswire (US)	Viatris Expands its Wellbeing Program with the Launch of Unmind, a Leading Workplace Resource Focused on Mental Health	NASDAQ:VTRS	Viatris Inc
16/04/2024	22h30	PR Newswire (US)	Viatris to Report First Quarter 2024 Financial Results on May 9, 2024	NASDAQ:VTRS	Viatris Inc
15/04/2024	14h00	PR Newswire (US)	Viatris Appoints Corinne Le Goff as Chief Commercial Officer	NASDAQ:VTRS	Viatris Inc
15/04/2024	12h59	PR Newswire (Canada)	Viatris Announces Launch of First Bioequivalent Generic Version of Copaxone® 20 mg/mL Once-Daily in Canada	NASDAQ:VTRS	Viatris Inc
15/04/2024	12h59	PR Newswire (Canada)	Viatris annonce le lancement de la première version générique bioéquivalente du Copaxone [MD] 20 mg/mL au Canada	NASDAQ:VTRS	Viatris Inc
01/04/2024	12h59	PR Newswire (US)	Viatris Announces the Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% in the United States	NASDAQ:VTRS	Viatris Inc
27/03/2024	11h59	PR Newswire (US)	Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline	NASDAQ:VTRS	Viatris Inc
06/03/2024	02h29	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VTRS	Viatris Inc
06/03/2024	01h26	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:VTRS	Viatris Inc
05/03/2024	00h11	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:VTRS	Viatris Inc
28/02/2024	12h30	PR Newswire (US)	Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance	NASDAQ:VTRS	Viatris Inc
28/02/2024	07h00	PR Newswire (US)	Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration	NASDAQ:VTRS	Viatris Inc
05/02/2024	12h59	PR Newswire (US)	Viatris to Announce Fourth Quarter and Full-Year 2023 Financial Results	NASDAQ:VTRS	Viatris Inc
30/01/2024	22h40	Edgar (US Regulatory)	Form 8-K/A - Current report: [Amend]	NASDAQ:VTRS	Viatris Inc
19/01/2024	12h56	PR Newswire (US)	Viatris recognised as a Top Employer 2024 in the UK for the second consecutive year	NASDAQ:VTRS	Viatris Inc
21/12/2023	22h05	PR Newswire (US)	Viatris to Participate in 42nd Annual J.P. Morgan Healthcare Conference	NASDAQ:VTRS	Viatris Inc
15/12/2023	22h45	PR Newswire (US)	Viatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora "Doretta" Mistras as Chief Financial Officer, Effective March 1, 2024, and Philippe Martin as Chief R&D Officer	NASDAQ:VTRS	Viatris Inc
15/12/2023	22h05	PR Newswire (US)	Viatris Shareholders Re-elect All Nominated Directors and Approve All Voting Matters at Annual Meeting of Shareholders	NASDAQ:VTRS	Viatris Inc
24/11/2023	22h30	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:VTRS	Viatris Inc
14/11/2023	14h00	PR Newswire (US)	Viatris to Participate in the Jefferies London Healthcare Conference	NASDAQ:VTRS	Viatris Inc
13/11/2023	14h00	PR Newswire (US)	Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)	NASDAQ:VTRS	Viatris Inc
07/11/2023	22h02	PR Newswire (US)	Viatris Reports Strong Financial and Operational Results for the Third Quarter 2023 and Reaffirms Full-Year 2023 Adjusted EBITDA and Free Cash Flow Guidance Ranges[1]	NASDAQ:VTRS	Viatris Inc
03/11/2023	21h36	Edgar (US Regulatory)	Form ARS - Annual Report to Security Holders	NASDAQ:VTRS	Viatris Inc
03/11/2023	21h31	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:VTRS	Viatris Inc
30/10/2023	14h00	PR Newswire (US)	Viatris to Host Webinar: The Power of Partnership to Address Antimicrobial Resistance	NASDAQ:VTRS	Viatris Inc